SUBSCRIBE
SUBSCRIBE
News   Business

Roche Holding AG Said to Return Diabetes Drug Rights to Ipsen Because of Side Effects

February 1, 2011 | 
1 min read
Bloomberg -- Roche Holding AG returned rights to the experimental diabetes drug taspoglutide to developer Ipsen SA after patients dropped out of trials because of side effects, according to two people with knowledge of the matter.
Alliances
Ipsen Biopharmaceuticals, Inc.
MORE ON THIS TOPIC
Contemporary art collage of hand holding an arrow showing fall. Modern design. Copy space.
Earnings
Moderna Misses Q1 Revenue Expectations, Plans Another $1.5B in Cuts
May 1, 2025
 · 
3 min read
 · 
Annalee Armstrong
Contemporary art collage. Hand put money to golden stack of coins, meaning income from investment. Concept of business strategy, investment, development, market, finance.
Earnings
Lilly’s Revenue Leaps 45% Thanks to Zepbound, Mounjaro, Of Course
May 1, 2025
 · 
1 min read
 · 
Annalee Armstrong
Paying double wages or giving double money, greed and lust, double work for double wages, one person splitting into two and claiming both
Deals
Novartis Strikes on M&A, Leading a Line of Big Pharmas With Cash to Spend
April 30, 2025
 · 
5 min read
 · 
Annalee Armstrong
command failed. Business team walk in a line following faulty orders vector
Layoffs
Entrada Cuts 20% of Workforce, Targeting Research Employees
April 30, 2025
 · 
1 min read
 · 
Angela Gabriel